Galectin Therapeutics Inc.
GALT
$3.98
-$0.18-4.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.34M | -45.19M | -47.05M | -45.08M | -44.29M |
| Total Depreciation and Amortization | 31.00K | 38.00K | 37.00K | 36.00K | 35.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.19M | 2.12M | 2.96M | 4.47M | 4.18M |
| Change in Net Operating Assets | 1.50M | 5.68M | 2.28M | 6.89M | 7.29M |
| Cash from Operations | -35.62M | -37.35M | -41.77M | -33.68M | -32.78M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 21.00M | 20.00M | 30.00M | 40.00M | 30.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.79M | 1.23M | 1.23M | 376.00K | 10.41M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 23.79M | 21.23M | 31.23M | 40.38M | 40.41M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.83M | -16.12M | -10.54M | 6.70M | 7.63M |